Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283139 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 834
- Enrollment target
NCT01283139 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 834 participants.
The verdict
NCT01283139, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 834 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).
Interventions
- OTHER Placebo
- BIOLOGICAL Sifalimumab 200 mg
- BIOLOGICAL Sifalimumab 600 mg
- BIOLOGICAL Sifalimumab 1,200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2011-03-31 |
| Est. Completion | 2014-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283139
The ClinicalTrials.gov registry entry for NCT01283139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 834 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01283139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283139 about?
NCT01283139 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus". To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT01283139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 834 participants. The study started on 2011-03-31. Estimated completion is 2014-04-17.
What interventions are being tested in trial NCT01283139?
The interventions under investigation include: Placebo (OTHER), Sifalimumab 200 mg (BIOLOGICAL), Sifalimumab 600 mg (BIOLOGICAL), Sifalimumab 1,200 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01283139?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.